Multi-center safety and efficacy study of a negative-pressure intraoral device in obstructive sleep apnea.

Obstructive sleep apnea Oral appliance treatment Sher criteria

Journal

Sleep medicine
ISSN: 1878-5506
Titre abrégé: Sleep Med
Pays: Netherlands
ID NLM: 100898759

Informations de publication

Date de publication:
17 Apr 2024
Historique:
received: 20 12 2023
revised: 10 04 2024
accepted: 11 04 2024
medline: 29 4 2024
pubmed: 29 4 2024
entrez: 28 4 2024
Statut: aheadofprint

Résumé

Intraoral devices, with or without negative oral pressure, can stabilize the oropharynx and reduce obstructive sleep apneas. We tested the hypothesis that treatment with the iNAP® Sleep Therapy System, which applies negative oral pressure through an intra-oral appliance, would reduce the severity of obstructive sleep apnea in a multi-center, prospective, first-night-randomized-order cross-over study. 130 patients fulfilled the entry criteria (age <75, AHI 15-55, BMI <33), and 63 entered the primary endpoint cohort (Total Sleep Time ≥4 h/night on the baseline polysomnogram and an oral negative vacuum time maintained by iNAP® ≥ 4 h/night and total sleep time ≥4 h/night during the first treatment study). 54 patients completed a second treatment sleep study at least 28 days after the first sleep study. Among the primary endpoint cohort (n = 63, age = 53.2 ± 11.3, BMI = 27.1 ± 2.8), 33 patients (52 %; 95 % confidence interval = 40%-64 %, p < 0.001) responded to iNAP treatment according to the Sher criteria (>50 % reduction in AHI and an AHI ≤20 events/hr). The average oxy-hemoglobin saturation increased by 1-2%, and the average percent oxygen desaturation decreased (was less severe) by 1 % while using the iNAP device. The incidence of adverse events, all self-limited, was low. The reduction in the apnea-hypopnea index was durable over the 28-day study. Patients used iNAP on average 5.6 h per night during the study period. The iNAP® Sleep Therapy System achieved a durable benefit in more than half the patients with moderate to severe obstructive sleep apnea and may be considered in patients who object to or failed continuous positive airway pressure. ClinicalTrials.gov Identifier: NCT02698059.

Sections du résumé

BACKGROUND BACKGROUND
Intraoral devices, with or without negative oral pressure, can stabilize the oropharynx and reduce obstructive sleep apneas. We tested the hypothesis that treatment with the iNAP® Sleep Therapy System, which applies negative oral pressure through an intra-oral appliance, would reduce the severity of obstructive sleep apnea in a multi-center, prospective, first-night-randomized-order cross-over study.
METHODS/PATIENTS METHODS
130 patients fulfilled the entry criteria (age <75, AHI 15-55, BMI <33), and 63 entered the primary endpoint cohort (Total Sleep Time ≥4 h/night on the baseline polysomnogram and an oral negative vacuum time maintained by iNAP® ≥ 4 h/night and total sleep time ≥4 h/night during the first treatment study). 54 patients completed a second treatment sleep study at least 28 days after the first sleep study.
RESULTS RESULTS
Among the primary endpoint cohort (n = 63, age = 53.2 ± 11.3, BMI = 27.1 ± 2.8), 33 patients (52 %; 95 % confidence interval = 40%-64 %, p < 0.001) responded to iNAP treatment according to the Sher criteria (>50 % reduction in AHI and an AHI ≤20 events/hr). The average oxy-hemoglobin saturation increased by 1-2%, and the average percent oxygen desaturation decreased (was less severe) by 1 % while using the iNAP device. The incidence of adverse events, all self-limited, was low. The reduction in the apnea-hypopnea index was durable over the 28-day study. Patients used iNAP on average 5.6 h per night during the study period.
CONCLUSION CONCLUSIONS
The iNAP® Sleep Therapy System achieved a durable benefit in more than half the patients with moderate to severe obstructive sleep apnea and may be considered in patients who object to or failed continuous positive airway pressure.
CLINICAL TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov Identifier: NCT02698059.

Identifiants

pubmed: 38678757
pii: S1389-9457(24)00183-7
doi: 10.1016/j.sleep.2024.04.015
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02698059']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

139-146

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing interest The corresponding author, on behalf of all the authors of this submission, disclose the following financial and/or personal relationships with other people or organizations that could inappropriately influence (bias) this work.

Auteurs

Georg Nilius (G)

Kliniken Essen-Mitte, Evang. Huyssens-Stiftung/Knappschaft gGmbH, Essen-Mitte, Germany; University Witten-Herdecke, Witten, Germany. Electronic address: G.Nilius@kem-med.com.

Mehran Farid-Moayer (M)

Peninsula Sleep Centre, Burlingame, CA, USA.

Chia-Mo Lin (CM)

Shin Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan.

Lennart Knaack (L)

INTERSOM Köln, Cologne, Germany.

Ying-Piao Wang (YP)

Mackay Memorial Hospital, Taipei Branch, Taipei City, Taiwan.

Dominic Dellweg (D)

Fachkrankenhaus Kloster Grafschaft GmbH, Schmallenberg, Germany.

Ricardo Stoohs (R)

Somnolab Schlaflabor, Essen/Dortmund, Germany.

Joachim Ficker (J)

3rd Medical Department (Respiratory Medicine) Klinikum Nuernberg, Paracelsus Medical University, Nuernberg, Germany.

Winfried Randerath (W)

Krankenhaus Bethanien, Solingen, Germany.

Markus B Specht (MB)

Zentrum für interdisziplinnäre Schlafmedizin, DKD Wiesbaden, Wiesbaden, Germany.

Wolfgang Galetke (W)

HELIOS Klinik Hagen, Hagen, Germany.

Hartmut Schneider (H)

American Sleep Clinic, Frankfurt, Germany.

Classifications MeSH